Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fallarino

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|February 6, 1999
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12F Fallarino, C Uyttenhove, T Boon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1996
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunizationT F Gajewski, F Fallarino, C Uyttenhove, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12T F Gajewski, F Fallarino, A Ashikari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2016
Aryl Hydrocarbon Receptor-Dependent Pathways in Immune RegulationM Gargaro, M Pirro, R Romani, et al.
International Immunology|April 20, 2001
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1AM A Markiewicz, F Fallarino, A Ashikari, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2000
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient miceA K Kacha, F Fallarino, M A Markiewicz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivoF Fallarino, U Grohmann, R Bianchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 10, 2001
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphataseT F Gajewski, F Fallarino, P E Fields, et al.
Transplantation Proceedings|March 27, 2001
Transplantation and the CD28/CTLA4/B7 pathwayM Alegre, F Fallarino, P Zhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2000
IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subsetU Grohmann, R Bianchi, M L Belladonna, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|February 6, 1999
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12F Fallarino, C Uyttenhove, T Boon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 15, 1996
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunizationT F Gajewski, F Fallarino, C Uyttenhove, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12T F Gajewski, F Fallarino, A Ashikari, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 12, 2016
Aryl Hydrocarbon Receptor-Dependent Pathways in Immune RegulationM Gargaro, M Pirro, R Romani, et al.
International Immunology|April 20, 2001
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1AM A Markiewicz, F Fallarino, A Ashikari, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 22, 2000
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient miceA K Kacha, F Fallarino, M A Markiewicz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 9, 2000
Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivoF Fallarino, U Grohmann, R Bianchi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 10, 2001
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphataseT F Gajewski, F Fallarino, P E Fields, et al.
Transplantation Proceedings|March 27, 2001
Transplantation and the CD28/CTLA4/B7 pathwayM Alegre, F Fallarino, P Zhou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 21, 2000
IFN-gamma inhibits presentation of a tumor/self peptide by CD8 alpha- dendritic cells via potentiation of the CD8 alpha+ subsetU Grohmann, R Bianchi, M L Belladonna, et al.
Pageof 4